Gastrointestinal Parameters That Influence Oral Medications

doi:10.1002/jps.2600820902

Journal of Pharmaceutical Sciences

Volume 82, Issue 9, September 1993, Pages 857-872

https://doi.org/10.1002/jps.2600820902 Get rights and content

Abstract

The successful functioning of oral medication depends primarily on how the gastrointestinal (Gl) tract processes drugs and drug delivery systems. Parameters such as regional pH, motility (and hence residence time), and brush border and colonic microflora enzymatic activity play an important role in the performance of orally administered dosage forms. In addition, medications are required to treat disease states that alter normal functions of the body. This review (which summarizes the symposium of the same title undertaken in the 2nd Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology, Jerusalem, Israel, May 1992) focuses on two aspects: (1) how some physiological parameters of the intestine can be manipulated to achieve control over drug absorption (P. Bass: alteration of the paracellular space of enterocytes with glucose to modulate the passive movement of drugs; E. Ziv: intestinal absorption of insulin) and spatial placement of drugs (D. R. Friend: use of colonic β-glucosidases to target glycoside prodrugs of steroids to the large bowel; A. Rubinstein: specific degradation of polysaccharide matrices by colonic bacteria); and (2) how abnormalities of the Gl tract affect drug performance (J. B. Dressman: physiological and pathophysiological changes in upper Gl tract pH may lead to alterations in drug bioavailability; W. A. Ritschel: influence of diseases on the pharmacokinetics of drugs).

References (100)

KohriN. et al.
Int. J. Pharm.
(1992)
StewartJ.J. et al.
Gastroenterology
(1976)
GulliksonG.W. et al.
Gastroenterology
(1977)
GaginellaT.S. et al.
Gastroenterology
(1977)
GrossmanM.I. et al.
Gastroenterology
(1961)
WaxJ. et al.
Gastroenterology
(1970)
LuH.-H. et al.
J. Pharm. Sci
(1992)
HankerJ.P.
Am. J. Obstet. Gynecol.
(1990)
FedorakR.N. et al.
Gastroenterology
(1990)
HsuL. et al.
Biochim. Biophys. Acta
(1965)

FriendD.R.

Adv. Drug Del. Rev.

(1991)

RubinsteinA. et al.

Int. J. Pharm.

(1992)

SalyersA.A. et al.

ZivE. et al.

Life Sci

(1981)

KidronM. et al.

Life Sci

(1982)

ZivE. et al.

Biochem. Pharmacol.

(1987)

DressmanJ.B. et al.

Pharm. Res.

(1990)

RussellT.L. et al.

Pharm. Res.

(1993)

Russell, T. L.; Berardi, R. R.; Barnett, J. L.; O'Sullivan, T. L.; Wagner, J. G.; Dressman, J. B. Pharm. Res., in...

RussellT.L. et al.

Proc. ACG 56th Annual Meeting

(1991)

BerardiR.R. et al.

Biopharm. Drug Dispos.

(1988)

YoungbergC.A. et al.

Dig. Dis. Sci.

(1987)

MuranishiS.

Crit. Rev. Ther. Drug Carrier Syst.

(1990)

SwensonE.S. et al.

Adv. Drug Del. Rev.

(1992)

GaginellaT.S. et al.

J. Pharmacol. Exp. Ther.

(1975)

GaginellaT.S. et al.

Life Sci

(1975)

ClineW.S. et al.

J. Clin. Invest.

(1976)

StewartJ.J. et al.

J. Pharmacol. Exp. Ther.

(1975)

GaginellaT.S. et al.

Life Sci

(1978)

GulliksonG.W. et al.

StewartJ.J. et al.

J. Pharmacol. Exp. Ther.

(1975)

GaginellaT.S. et al.

J. Pharmacol. Exp. Ther.

(1977)

SeeN.A. et al.

Dig. Dis. Sci.

(1992)

GulliksonG.W. et al.

J. Pharmacol. Exp. Ther.

(1981)

N. A. Ph.D. Thesis

(1991)

BjamasonI. et al.

Gastroenterology

(1992)

RitschelW.A. et al.

BeyssacE. et al.

Methods Find. Exp. Clin. Pharmacol.

(1991)

LangmanM.J.S.

HowardP.J. et al.

NimmoW.S.

Clin. Pharmacokinet.

(1976)

SanchezJ. et al.

J. Clin. Pharmacol.

(1989)

BrysonJ.C. et al.

J. Clin. Pharmacol.

(1989)

PottageA. et al.

J. Pharm. Pharmacol.

(1974)

BlumR.A. et al.

Ann. Intern. Med.

(1991)

GwiltP.R. et al.

Clin. Pharmacokinet.

(1991)

KearnsG.L. et al.

Clin. Pharmacokinet.

(1989)

SmithR.S.

Br. Med. J.

(1964)

HarperK.J. et al.

Drug Intell. Clin. Pharm.

(1989)

GoldfingerS.E.

Harvard Health Lett

(1992)

Cited by (70)

Clinical translation of oral peptide delivery technologies
2022, Oral Delivery of Therapeutic Peptides and Proteins
Clinical translations are a critical component for developing oral peptide dosage forms as an alternative to injections. This is particularly important given the variability between several preclinical species and the poor in vitro/in vivo correlations observed during the development of oral dosage forms. In addition to efficacy and safety, clinical studies provide statistical handles on the bioavailability and variability which are important to develop dosage forms. Several peptides have been advanced to the clinic in the last two decades but with limited success. In this chapter we review some of the early clinical studies of oral peptides ranging from insulin to the most recently approved semaglutide. We summarize clinical designs and success criteria outlined (where available) in these studies and highlight potential reasons for variability based on GI parameters between human subjects such as surface areas, transit time variations, and intestinal permeability. Futuristic considerations for oral peptide translational studies including digital technologies have been outlined as well.
Micellar buccal film for safe and effective control of seizures: Preparation, in vitro characterization, ex vivo permeation studies and in vivo assessment
2021, European Journal of Pharmaceutical Sciences
Citation Excerpt :
Considering the different routes of administration, the oral route remains the safest, convenient, and economical one, suitable for different types of drug candidates, in addition to the ease of transportation and storage (Ronchi et al., 2019). Unlikely, oral administration confronts some physiological obstacles owing to several factors, comprising the surface area of the GIT system, gastrointestinal transit time, commensal flora, pH, and enzymatic activity (Dressman et al., 1993). The buccal administration route can readily replace the oral delivery avoiding the aforementioned constraints.
The current research article focused on formulating an easily applied, water-based buccal film loaded with the antiepileptic drug, lamotrigine (LTG). The designed film can be comfortably administered by epileptic patients to ensure a controllable therapeutic efficacy against seizures. The solubility of LTG in water was significantly improved by micellar solubilization. Upon testing several surfactants, three of them (Synperonic PE/P84, Brij L23, and Brij 78) achieved maximum possible solubility for LTG and were characterized for their micellar size, cloud point, and % transmittance. Selected micellar systems were incorporated within a buccal film prepared using solvent casting method based on either gelatin or polyvinylpyrrolidone (3%w/v) with 1.5%w/v propylene glycol as a plasticizer. Different micellar films were characterized for their physicochemical characteristics, swelling index, folding endurance, drug content uniformity, and in vitro LTG release. From the tested formulations, one formulation; LTG-BF1 (in which Brij 78 was used for the micellar solubilization and gelatin as the matrix former), was selected as the optimum and extensively studied for mucoadhesion, ex vivo permeation studies by Franz diffusion cells and confocal laser scanning microscopy. Results showed superior enhanced permeation of micellar film. LTG-BF1 was evaluated for the in vivo performance using rats. Status epilepticus was induced in rats by injecting Pentylenetetrazol (PTZ) i.p. at an initial dose of 30 mg/kg, followed by 10 mg/kg every10 min till 60 min. A group of rats receiving the designed buccal formulation (20 mg/kg) was compared with a group receiving the same dose of the oral market product and the normal control and PTZ groups. Rats receiving LTG-BF1 recorded reduced seizure scores at all stages, longer latency time, and higher threshold PTZ dose compared to PTZ and market product groups. In addition, LTG-BF1 reduced brain concentrations of TNF-α and TGF-β with an elevation of EAAT2 and GABA brain contents compared to PTZ and market product groups and ameliorated neuronal damage. In conclusion, LTG-loaded buccal micellar film proved a superior antiepileptic effect in PTZ induced acute epileptic model.
Development and evaluation of budesonide-based modified-release liquid oral dosage forms
2019, Journal of Drug Delivery Science and Technology
Citation Excerpt :
This is done to protect the loaded drugs from biological fluids or potential issues imposed by the physiologic variabilities of gastrointestinal tract (GIT) (e.g. pH, the commensal flora, enzymatic activity, surface area and gastrointestinal transit time). It also prevents delivery of the drug outside the so-called absorption window, ensuring its release in the target site as extensively as possible [8]. An example of this latter case is colon delivery, for which it is necessary to prevent the release of active ingredients in the entire gastric residence and the small intestinal transit.
Modified-release oral drug delivery dosage forms are widely used in the pharmaceutical field to overcome all the potential issues imposed by the physiological variabilities of the gastrointestinal tract as well as to maintain drug concentrations within the therapeutic window. In the market, they are available only as solid dosage forms such as capsules or tablets. The development of a liquid oral dosage form with modified-release properties has been keenly awaited. This form could increase the compliance of patients with a swallowing impairment (i.e. paediatric, older or critically ill patients) and, consequently, the efficacy of the therapeutic treatment. In this study, budesonide was used as a model drug to develop a modified-release liquid oral dosage form (i.e. colonic-release, sustained-release). For this purpose, multi-layered particles were obtained, starting from small microcrystalline cellulose neutral cores (Cellets® with a mean diameter lower than 500 μm), in a lab-scale fluid-bed coater. Poly(meth)acrylate polymers commonly available under the trade name of Eudragit®, such as S100, RS PO, RL100 and E100, were used to get defined drug release profiles. They were also used to guarantee the stability of the reconstituted liquid syrup during 2 weeks of storage at room temperature.
Development and evaluation of an omeprazole-based delayed-release liquid oral dosage form
2019, International Journal of Pharmaceutics
Citation Excerpt :
Above all, the oral route improves patient compliance (Pinto, 2010). However, oral administration faces some physiological constraints due to the heterogeneity of the gastrointestinal system (e.g. pH, the commensal flora, gastrointestinal transit time, enzymatic activity and surface area) (Dressman et al., 1993). Conventional dosage forms do not allow all the potential issues imposed by the physiology of gastrointestinal tract to be overcome or to provide controlled release of the drug.
Modified-release oral dosage forms are commonly used in pharmaceutics to delay or sustain the release of drugs. Nowadays, they are only marketed as solid dosage forms such as capsules or tablets. Therefore, the development of a liquid oral dosage form with modified-release properties has been keenly awaited to increase the compliance of patients with a swallowing impairment, such as paediatric, older or critically ill patients. In this study, a new technology has been developed that consists of multi-layered particles suspended extemporaneously in a syrup, using omeprazole as a model drug. The coating procedure was optimized to obtain a yield of minimum 90% w/w and a mean diameter below 500 µm. Eudragit® E100 and Eudragit® L100-55 were used to prevent the early release of omeprazole in the syrup and in the acidic environment of the stomach, respectively. These polymers allowed the stability of the coated particles to be ensured when dispersed in a liquid and the enteric release of the drug to be targeted. It was demonstrated that our new system presented similar release performances to existing marketed enteric dosage forms. It is able to protect omeprazole for 2 h in acidic medium at pH 1.2, while omeprazole was entirely released at pH 6.8 within 45 min. Once the final suspension is prepared extemporaneously, it presents sufficient stability to guarantee the administration of multiple doses filled into a syrup bottle and kept for a limited storage time at room temperature (e.g. up to 10 doses to be administered within 10 days).
A Delivery System for Oral Administration of Proteins/Peptides Through Bile Acid Transport Channels
2019, Journal of Pharmaceutical Sciences
Proteins and peptides are poorly absorbed via oral administration because of the gastrointestinal tract environment and lysosomal digestion after apical endocytosis. A delivery system, consisting of a deoxycholic acid–conjugated nanometer-sized carrier, may enhance the absorption of proteins in the intestine via the bile acid pathway. Deoxycholic acid is first conjugated to chitosan. Liposomes are then prepared and loaded with the model drug insulin. Finally, the conjugates are bound to the liposome surface to form deoxycholic acid and chitosan conjugate–modified liposomes (DC-LIPs). This study demonstrates that DC-LIPs can promote the intestinal absorption of insulin via the apical sodium-dependent bile acid transporter, based on observing fluorescently stained tissue slices of the rat small intestine and a Caco-2 cell uptake experiment. Images of intestinal slices revealed that excellent absorption of DC-LIPs is achieved via apical sodium-dependent bile acid transporter, and a flow cytometry experiment proved that DC-LIPs are a highly efficient delivery carrier. Caco-2 cells were also used to study the lysosome escape ability of DC-LIPs. We learned from confocal microscopy photographs that DC-LIPs can protect their contents from being destroyed by the lysosome. Finally, according to pharmacokinetic analyses, insulin-loaded DC-LIPs show a significant hypoglycemic effect with an oral bioavailability of 16.1% in rats with type I diabetes.
Oral peptide delivery: Translational challenges due to physiological effects
2018, Journal of Controlled Release
Citation Excerpt :
In addition to inter subject variations, diseases can also alter the gastric emptying time. Achlorhydria has been shown to go together with delayed gastric emptying [50]. In a study comprising of elderly achlorhydria patients, it was observed that, on an average, the patients took 40 min to empty 50% of a 300 mL of consumed orange juice.
Oral delivery of peptide therapeutics as a convenient alternate to injections has been an area of research for the pharmaceutical scientific community for the last several decades. However, systemic delivery of therapeutic peptides via the oral route has been a daunting task due to the low pH denaturation of the peptides in the stomach, enzymatic instability, and poor transport across the tight junctions resulting in very low bioavailability. The low bioavailability is accompanied by large intra- and inter-subject variability leading to translational issues, preventing the development of successful peptide therapeutics. The inter-subject variability leads to large differences in pharmacologic responses in individuals and thus the dose required to produce therapeutic effect could vary between individuals making the development of drug product a very difficult task. A substantial amount of research has been (and continues to be) performed with a focus on getting acceptable absorption and reproducible results. Nonetheless, the high variability and low bioavailability during oral administration of peptides is still a work in progress and under-explored in a systematic way. While there are several review articles and scattered publications that discuss potential technologies for oral peptide delivery, a detailed look into the physiological challenges and absorption barriers which are a hindrance to successful clinical translation, is lacking. Herein, we have analyzed the physiological barriers within the gastrointestinal (GI) tract that are the root causes for the low bioavailability and high variability of oral delivery of peptides in humans. In particular, we have taken a detailed look at the key influencing factors such as the nature of various GI tract parameters, components of the GI tract that influences the uptake, site of absorption, pH of the gastric and intestinal compartments, food effect, and role of peptidases in affecting oral peptide absorption. Lack of in vitro - in vivo correlations and variability in animal models have also been highlighted as key impediments in understanding the challenges. The unique perspective presented herein for overcoming the physiological absorption barriers, will offer better developability approaches and will positively impact clinical translation of future oral peptide therapeutics. A deep understanding of these effects are vital, given the emergence of microbiome and oral biologic drug delivery that are fast emerging as the next wave of personalized patient centric therapies.

View all citing articles on Scopus

View full text

Symposium Review ArticlesGastrointestinal Parameters That Influence Oral Medications

Abstract

Int. J. Pharm.

Gastroenterology

Gastroenterology

Gastroenterology

Gastroenterology

Gastroenterology

J. Pharm. Sci

Am. J. Obstet. Gynecol.

Gastroenterology

Biochim. Biophys. Acta

Adv. Drug Del. Rev.

Int. J. Pharm.

Life Sci

Life Sci

Biochem. Pharmacol.

Pharm. Res.

Pharm. Res.

Proc. ACG 56th Annual Meeting

Biopharm. Drug Dispos.

Dig. Dis. Sci.

Crit. Rev. Ther. Drug Carrier Syst.

Adv. Drug Del. Rev.

J. Pharmacol. Exp. Ther.

Life Sci

J. Clin. Invest.

J. Pharmacol. Exp. Ther.

Life Sci

J. Pharmacol. Exp. Ther.

J. Pharmacol. Exp. Ther.

Dig. Dis. Sci.

J. Pharmacol. Exp. Ther.

N. A. Ph.D. Thesis

Gastroenterology

Methods Find. Exp. Clin. Pharmacol.

Clin. Pharmacokinet.

J. Clin. Pharmacol.

J. Clin. Pharmacol.

J. Pharm. Pharmacol.

Ann. Intern. Med.

Clin. Pharmacokinet.

Clin. Pharmacokinet.

Br. Med. J.

Drug Intell. Clin. Pharm.

Harvard Health Lett

Symposium Review Articles
Gastrointestinal Parameters That Influence Oral Medications